newsfilter
← Latest News
ACCESS Newswire·

Kadmon Announces 12 Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting

- ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively -